Document and Entity Information
Document and Entity Information Document - shares | 3 Months Ended | |
Mar. 31, 2019 | Apr. 30, 2019 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Entitiy Registrant Name | UNITEDHEALTH GROUP INC | |
Entitiy Central Index Key | 0000731766 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Common Stock, Shares Outstanding | 950,343,113 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash and cash equivalents | $ 12,407 | $ 10,866 |
Short-term investments | 3,303 | 3,458 |
Accounts receivable, net | 12,826 | 11,388 |
Other current receivables, net | 7,631 | 6,862 |
Assets under management | 2,951 | 3,032 |
Prepaid expenses and other current assets | 3,697 | 3,086 |
Total current assets | 42,815 | 38,692 |
Long-term investments | 33,553 | 32,510 |
Property, equipment and capitalized software, net | 8,230 | 8,458 |
Goodwill | 59,379 | 58,910 |
Other intangible assets, net | 9,245 | 9,325 |
Other assets | 7,975 | 4,326 |
Total assets | 161,197 | 152,221 |
Current liabilities: | ||
Medical costs payable | 21,139 | 19,891 |
Accounts payable and accrued liabilities | 16,900 | 16,705 |
Commercial paper and current maturities of long-term debt | 3,919 | 1,973 |
Unearned revenues | 2,530 | 2,396 |
Other current liabilities | 14,445 | 12,244 |
Total current liabilities | 58,933 | 53,209 |
Long-term debt, less current maturities | 34,419 | 34,581 |
Deferred income taxes | 2,786 | 2,474 |
Other liabilities | 8,554 | 5,730 |
Total liabilities | 104,692 | 95,994 |
Commitments and contingencies (Note 6) | ||
Redeemable noncontrolling interests | 2,054 | 1,908 |
Equity: | ||
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding | 0 | 0 |
Common stock, $0.01 par value - 3,000 shares authorized; 953 and 960 issued and outstanding | 10 | 10 |
Retained earnings | 55,472 | 55,846 |
Accumulated other comprehensive loss | (3,758) | (4,160) |
Nonredeemable noncontrolling interests | 2,727 | 2,623 |
Total equity | 54,451 | 54,319 |
Total liabilities, redeemable noncontrolling interests and equity | $ 161,197 | $ 152,221 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheet (Parenthetical) - $ / shares shares in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 3,000 | 3,000 |
Common stock, shares issued | 953 | 960 |
Common stock, shares outstanding | 953 | 960 |
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 10 | 10 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Revenues: | ||
Premiums | $ 47,513 | $ 44,084 |
Products | 8,072 | 6,702 |
Services | 4,318 | 4,104 |
Investment and other income | 405 | 298 |
Total revenues | 60,308 | 55,188 |
Operating costs: | ||
Medical costs | 38,939 | 35,863 |
Operating costs | 8,517 | 8,506 |
Cost of products sold | 7,381 | 6,184 |
Depreciation and amortization | 639 | 582 |
Total operating costs | 55,476 | 51,135 |
Earnings from operations | 4,832 | 4,053 |
Interest expense | (400) | (329) |
Earnings before income taxes | 4,432 | 3,724 |
Provision for income taxes | (875) | (800) |
Net earnings | 3,557 | 2,924 |
Earnings attributable to noncontrolling interests | (90) | (88) |
Net earnings attributable to UnitedHealth Group common shareholders | $ 3,467 | $ 2,836 |
Earnings per share attributable to UnitedHealth Group common shareholders: | ||
Basic | $ 3.62 | $ 2.94 |
Diluted | $ 3.56 | $ 2.87 |
Basic weighted-average number of common shares outstanding | 958 | 966 |
Dilutive effect of common share equivalents | 17 | 21 |
Diluted weighted-average number of common shares outstanding | 975 | 987 |
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents | 8 | 7 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Net earnings | $ 3,557 | $ 2,924 |
Other comprehensive income (loss): | ||
Gross unrealized gains (losses) on investment securities during the period | 520 | (378) |
Income tax effect | (119) | 86 |
Total unrealized gains (losses), net of tax | 401 | (292) |
Gross reclassification adjustment for net realized losses (gains) included in net earnings | 4 | (19) |
Income tax effect | (1) | 4 |
Total reclassification adjustment, net of tax | 3 | (15) |
Total foreign currency translation losses | (2) | (1) |
Other comprehensive income (loss) | 402 | (308) |
Comprehensive income | 3,959 | 2,616 |
Comprehensive income attributable to noncontrolling interests | (90) | (88) |
Comprehensive income attributable to UnitedHealth Group common shareholders | $ 3,869 | $ 2,528 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Equity - USD ($) shares in Millions, $ in Millions | Total | Common Stock [Member] | Additional Paid-In Capital [Member] | Retained Earnings [Member] | Net Unrealized (Losses) Gains on Investments [Member] | Foreign Currency Translation [Member] | Nonredeemable Noncontrolling Interests [Member] |
Balance at Dec. 31, 2017 | $ 49,833 | $ 10 | $ 1,703 | $ 48,730 | $ (13) | $ (2,654) | $ 2,057 |
Balance (in shares) at Dec. 31, 2017 | 969 | ||||||
Adjustment to adopt ASU at Dec. 31, 2017 | 0 | (24) | 24 | ||||
Net earnings attributable to UnitedHealth Group common shareholders | 2,836 | 2,836 | |||||
Net earnings attributable to nonredeemable noncontrolling interest | 53 | ||||||
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest | 2,889 | ||||||
Other comprehensive income (loss) | (308) | (307) | (1) | ||||
Issuances of common stock, and related tax effects (in shares) | 5 | ||||||
Issuances of common stock, and related tax effects | 415 | $ 0 | 415 | ||||
Share-based compensation | 206 | 206 | |||||
Common share repurchases (in shares) | (12) | ||||||
Common share repurchases | (2,650) | $ 0 | (2,324) | (326) | |||
Cash dividends paid on common shares ($0.90 per share and $0.75 per share for three months ended March 31, 2019 and March 31, 2018, respectively) | (722) | (722) | |||||
Acquisition and other adjustments of nonredeemable noncontrolling interests | 423 | 423 | |||||
Distribution to nonredeemable noncontrolling interests | (50) | (50) | |||||
Balance at Mar. 31, 2018 | 50,036 | $ 10 | 0 | 50,494 | (296) | (2,655) | 2,483 |
Balance (in shares) at Mar. 31, 2018 | 962 | ||||||
Balance at Dec. 31, 2018 | $ 54,319 | $ 10 | 0 | 55,846 | (264) | (3,896) | 2,623 |
Balance (in shares) at Dec. 31, 2018 | 960 | 960 | |||||
Adjustment to adopt ASU at Dec. 31, 2018 | $ (18) | (13) | (5) | ||||
Net earnings attributable to UnitedHealth Group common shareholders | 3,467 | 3,467 | |||||
Net earnings attributable to nonredeemable noncontrolling interest | 60 | ||||||
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest | 3,527 | ||||||
Other comprehensive income (loss) | 402 | 404 | (2) | ||||
Issuances of common stock, and related tax effects (in shares) | 5 | ||||||
Issuances of common stock, and related tax effects | 56 | $ 0 | 56 | ||||
Share-based compensation | 239 | 239 | |||||
Common share repurchases (in shares) | (12) | ||||||
Common share repurchases | (3,002) | $ 0 | (34) | (2,968) | |||
Cash dividends paid on common shares ($0.90 per share and $0.75 per share for three months ended March 31, 2019 and March 31, 2018, respectively) | (860) | (860) | |||||
Redeemable noncontrolling interests fair value and other adjustments | (152) | (152) | |||||
Acquisition and other adjustments of nonredeemable noncontrolling interests | 23 | (109) | 132 | ||||
Distribution to nonredeemable noncontrolling interests | (83) | (83) | |||||
Balance at Mar. 31, 2019 | $ 54,451 | $ 10 | $ 0 | $ 55,472 | $ 140 | $ (3,898) | $ 2,727 |
Balance (in shares) at Mar. 31, 2019 | 953 | 953 |
Condensed Consolidated Statem_4
Condensed Consolidated Statement of Changes in Equity (Parenthetical) - $ / shares | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Statement of Stockholders' Equity [Abstract] | ||
Common Stock, Dividends, Per Share, Cash Paid | $ 0.90 | $ 0.75 |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Operating activities | ||
Net earnings | $ 3,557 | $ 2,924 |
Noncash items: | ||
Depreciation and amortization | 639 | 582 |
Deferred income taxes | 134 | (74) |
Share-based compensation | 243 | 208 |
Other, net | 42 | 27 |
Net change in other operating items, net of effects from acquisitions and changes in AARP balances: | ||
Accounts receivable | (1,421) | (1,579) |
Other assets | (1,495) | (3,232) |
Medical costs payable | 1,125 | 1,313 |
Accounts payable and other liabilities | 318 | 2,821 |
Unearned revenues | 92 | 5,379 |
Cash flows from operating activities | 3,234 | 8,369 |
Investing activities | ||
Purchases of investments | (3,540) | (3,891) |
Sales of investments | 1,510 | 1,002 |
Maturities of investments | 1,711 | 1,504 |
Cash paid for acquisitions, net of cash assumed | (689) | (2,583) |
Purchases of property, equipment and capitalized software | (562) | (477) |
Other, net | 154 | (72) |
Cash flows used for investing activities | (1,416) | (4,517) |
Financing activities | ||
Common share repurchases | (3,002) | (2,650) |
Cash dividends paid | (860) | (722) |
Proceeds from common stock issuances | 323 | 295 |
Repayments of long-term debt | (1,250) | (1,100) |
Proceeds from commercial paper, net | 3,101 | 4,259 |
Customer funds administered | 1,784 | 2,962 |
Other, net | (368) | (622) |
Cash flows (used for) from financing activities | (272) | 2,422 |
Effect of exchange rate changes on cash and cash equivalents | (5) | (12) |
Increase in cash and cash equivalents | 1,541 | 6,262 |
Cash and cash equivalents, beginning of period | 10,866 | 11,981 |
Cash and cash equivalents, end of period | $ 12,407 | $ 18,243 |
Basis of Presentation (Notes)
Basis of Presentation (Notes) | 3 Months Ended |
Mar. 31, 2019 | |
Basis of Presentation and Significant Accounting Policies [Text Block] | Basis of Presentation UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a diversified health care company dedicated to helping people live healthier lives and helping make the health system work better for everyone. Through its diversified family of businesses, the Company leverages core competencies in data and health information; advanced technology; and clinical expertise. These core competencies are deployed within two distinct, but strategically aligned, business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum. The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the SEC ( 2018 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly. Use of Estimates These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates include medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted. Recently Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2016-02, “Leases (Topic 842)” as modified by ASUs 2018-01, 2018-10, 2018-11, 2018-20 and 2019-01 (collectively, ASU 2016-02). Under ASU 2016-02, an entity is required to recognize assets and liabilities for the rights and obligations created by leases on the entity’s balance sheet for both finance and operating leases. The Company adopted ASU 2016-02 using a cumulative-effect upon adoption approach as of January 1, 2019. Upon adoption, the Company recognized $3.3 billion of lease right-of-use (ROU) assets and liabilities for operating leases on its Condensed Consolidated Balance Sheet, of which, $668 million were classified as current liabilities. The adoption of ASU 2016-02 was immaterial to the Company’s consolidated results of operations, equity and cash flows. The Company has included the disclosures required by ASU 2016-02 below and in Note 6, “Commitments and Contingencies” . The Company leases facilities and equipment under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not implicit in a lease, the Company utilizes its incremental borrowing rate for a period that closely matches the lease term. The Company’s ROU assets are included in other assets, and lease liabilities are included in other current liabilities and other liabilities in the Company’s Condensed Consolidated Balance Sheet. The Company has determined that there have been no other recently adopted or issued accounting standards that had, or will have, a material impact on its Condensed Consolidated Financial Statements. |
Investments (Notes)
Investments (Notes) | 3 Months Ended |
Mar. 31, 2019 | |
Investments [Abstract] | |
Investments [Text Block] | Investments A summary of debt securities by major security type is as follows: (in millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value March 31, 2019 Debt securities - available-for-sale: U.S. government and agency obligations $ 3,610 $ 30 $ (19 ) $ 3,621 State and municipal obligations 6,566 150 (9 ) 6,707 Corporate obligations 15,589 95 (58 ) 15,626 U.S. agency mortgage-backed securities 5,212 37 (51 ) 5,198 Non-U.S. agency mortgage-backed securities 1,471 13 (6 ) 1,478 Total debt securities - available-for-sale 32,448 325 (143 ) 32,630 Debt securities - held-to-maturity: U.S. government and agency obligations 265 — (1 ) 264 State and municipal obligations 31 1 — 32 Corporate obligations 428 1 — 429 Total debt securities - held-to-maturity 724 2 (1 ) 725 Total debt securities $ 33,172 $ 327 $ (144 ) $ 33,355 December 31, 2018 Debt securities - available-for-sale: U.S. government and agency obligations $ 3,434 $ 13 $ (42 ) $ 3,405 State and municipal obligations 7,117 61 (57 ) 7,121 Corporate obligations 15,366 14 (218 ) 15,162 U.S. agency mortgage-backed securities 4,947 11 (106 ) 4,852 Non-U.S. agency mortgage-backed securities 1,376 2 (20 ) 1,358 Total debt securities - available-for-sale 32,240 101 (443 ) 31,898 Debt securities - held-to-maturity: U.S. government and agency obligations 255 1 (2 ) 254 State and municipal obligations 11 — — 11 Corporate obligations 355 — — 355 Total debt securities - held-to-maturity 621 1 (2 ) 620 Total debt securities $ 32,861 $ 102 $ (445 ) $ 32,518 The Company held $2.0 billion of equity securities as of March 31, 2019 and December 31, 2018 . The Company’s investments in equity securities primarily consist of employee savings plan related investments, shares of Brazilian real denominated fixed-income funds and dividend paying stocks with readily determinable fair values. Additionally, the Company’s investments included $1.5 billion of equity method investments in operating businesses in the health care sector as of March 31, 2019 and December 31, 2018 . The amortized cost and fair value of debt securities as of March 31, 2019 , by contractual maturity, were as follows: Available-for-Sale Held-to-Maturity (in millions) Amortized Cost Fair Value Amortized Fair Due in one year or less $ 3,457 $ 3,455 $ 132 $ 132 Due after one year through five years 12,283 12,304 318 318 Due after five years through ten years 7,314 7,430 131 131 Due after ten years 2,711 2,765 143 144 U.S. agency mortgage-backed securities 5,212 5,198 — — Non-U.S. agency mortgage-backed securities 1,471 1,478 — — Total debt securities $ 32,448 $ 32,630 $ 724 $ 725 The fair value of available-for-sale debt securities with gross unrealized losses by security type and length of time that individual securities have been in a continuous unrealized loss position were as follows: Less Than 12 Months 12 Months or Greater Total (in millions) Fair Value Gross Unrealized Losses Fair Value Gross Fair Value Gross March 31, 2019 Debt securities - available-for-sale: U.S. government and agency obligations $ — $ — $ 1,329 $ (19 ) $ 1,329 $ (19 ) State and municipal obligations — — 1,274 (9 ) 1,274 (9 ) Corporate obligations 1,461 (7 ) 5,479 (51 ) 6,940 (58 ) U.S. agency mortgage-backed securities — — 2,979 (51 ) 2,979 (51 ) Non-U.S. agency mortgage-backed securities — — 546 (6 ) 546 (6 ) Total debt securities - available-for-sale $ 1,461 $ (7 ) $ 11,607 $ (136 ) $ 13,068 $ (143 ) December 31, 2018 Debt securities - available-for-sale: U.S. government and agency obligations $ 998 $ (7 ) $ 1,425 $ (35 ) $ 2,423 $ (42 ) State and municipal obligations 1,334 (11 ) 2,491 (46 ) 3,825 (57 ) Corporate obligations 8,105 (109 ) 4,239 (109 ) 12,344 (218 ) U.S. agency mortgage-backed securities 1,296 (22 ) 2,388 (84 ) 3,684 (106 ) Non-U.S. agency mortgage-backed securities 622 (7 ) 459 (13 ) 1,081 (20 ) Total debt securities - available-for-sale $ 12,355 $ (156 ) $ 11,002 $ (287 ) $ 23,357 $ (443 ) The Company’s unrealized losses from debt securities as of March 31, 2019 were generated from 11,000 positions out of a total of 30,000 positions. The Company believes that it will collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, noting no significant deterioration since purchase. As of March 31, 2019 , the Company did not have the intent to sell any of the securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. |
Fair Value (Notes)
Fair Value (Notes) | 3 Months Ended |
Mar. 31, 2019 | |
Fair Value Disclosures [Abstract] | |
Fair Value [Text Block] | Fair Value Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2018 10-K. The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices in Active Markets (Level 1) Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Total Fair and Carrying Value March 31, 2019 Cash and cash equivalents $ 12,283 $ 124 $ — $ 12,407 Debt securities - available-for-sale: U.S. government and agency obligations 3,319 302 — 3,621 State and municipal obligations — 6,707 — 6,707 Corporate obligations 17 15,424 185 15,626 U.S. agency mortgage-backed securities — 5,198 — 5,198 Non-U.S. agency mortgage-backed securities — 1,478 — 1,478 Total debt securities - available-for-sale 3,336 29,109 185 32,630 Equity securities 1,827 12 — 1,839 Assets under management 896 2,043 12 2,951 Total assets at fair value $ 18,342 $ 31,288 $ 197 $ 49,827 Percentage of total assets at fair value 37 % 63 % — % 100 % December 31, 2018 Cash and cash equivalents $ 10,757 $ 109 $ — $ 10,866 Debt securities - available-for-sale: U.S. government and agency obligations 3,060 345 — 3,405 State and municipal obligations — 7,121 — 7,121 Corporate obligations 39 14,950 173 15,162 U.S. agency mortgage-backed securities — 4,852 — 4,852 Non-U.S. agency mortgage-backed securities — 1,358 — 1,358 Total debt securities - available-for-sale 3,099 28,626 173 31,898 Equity securities 1,832 13 — 1,845 Assets under management 1,086 1,938 8 3,032 Total assets at fair value $ 16,774 $ 30,686 $ 181 $ 47,641 Percentage of total assets at fair value 35 % 65 % — % 100 % There were no transfers in or out of Level 3 financial assets or liabilities during the three months ended March 31, 2019 or 2018 . The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices in Active Markets (Level 1) Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Total Fair Value Total Carrying Value March 31, 2019 Debt securities - held-to-maturity $ 273 $ 172 $ 280 $ 725 $ 724 Long-term debt and other financing obligations — 37,790 — 37,790 35,221 December 31, 2018 Debt securities - held-to-maturity $ 260 $ 65 $ 295 $ 620 $ 621 Long-term debt and other financing obligations $ — $ 37,944 $ — $ 37,944 $ 36,554 Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during the three months ended March 31, 2019 or 2018 . |
Medical Costs Payable (Notes)
Medical Costs Payable (Notes) | 3 Months Ended |
Mar. 31, 2019 | |
Medical Costs Payable Text Block | Medical Costs Payable The following table shows the components of the change in medical costs payable for the three months ended March 31: (in millions) 2019 2018 Medical costs payable, beginning of period $ 19,891 $ 17,871 Acquisitions 35 211 Reported medical costs: Current year 39,239 36,153 Prior years (300 ) (290 ) Total reported medical costs 38,939 35,863 Medical payments: Payments for current year (22,973 ) (21,237 ) Payments for prior years (14,753 ) (13,119 ) Total medical payments (37,726 ) (34,356 ) Medical costs payable, end of period $ 21,139 $ 19,589 For the three months ended March 31, 2019 and 2018 , the medical cost reserve development included no individual factors that were significant. Medical costs payable included reserves for claims incurred by insured customers but not yet reported to the Company of $14.3 billion and $13.2 billion at March 31, 2019 and December 31, 2018 , respectively. |
Commercial Paper and Long-Term
Commercial Paper and Long-Term Debt (Notes) | 3 Months Ended |
Mar. 31, 2019 | |
Debt Disclosure [Abstract] | |
Commercial Paper and Long-Term Debt [Text Block] | Commercial Paper and Long-Term Debt Commercial paper and senior unsecured long-term debt consisted of the following: March 31, 2019 December 31, 2018 (in millions, except percentages) Par Value Carrying Value Fair Value Par Value Carrying Value Fair Value Commercial paper $ 3,134 $ 3,117 $ 3,117 $ — $ — $ — 1.700% notes due February 2019 — — — 750 750 749 1.625% notes due March 2019 — — — 500 500 499 2.300% notes due December 2019 500 496 499 500 494 497 2.700% notes due July 2020 1,500 1,498 1,503 1,500 1,498 1,494 Floating rate notes due October 2020 300 299 300 300 299 298 3.875% notes due October 2020 450 445 457 450 443 456 1.950% notes due October 2020 900 897 890 900 897 884 4.700% notes due February 2021 400 400 413 400 398 412 2.125% notes due March 2021 750 748 744 750 747 734 Floating rate notes due June 2021 350 349 350 350 349 347 3.150% notes due June 2021 400 399 404 400 399 400 3.375% notes due November 2021 500 493 508 500 489 503 2.875% notes due December 2021 750 742 754 750 735 748 2.875% notes due March 2022 1,100 1,063 1,107 1,100 1,051 1,091 3.350% notes due July 2022 1,000 997 1,022 1,000 997 1,005 2.375% notes due October 2022 900 895 891 900 894 872 0.000% notes due November 2022 15 12 13 15 12 13 2.750% notes due February 2023 625 610 625 625 602 611 2.875% notes due March 2023 750 758 754 750 750 739 3.500% notes due June 2023 750 747 773 750 746 756 3.500% notes due February 2024 750 745 772 750 745 755 3.750% notes due July 2025 2,000 1,989 2,088 2,000 1,989 2,025 3.700% notes due December 2025 300 298 312 300 298 303 3.100% notes due March 2026 1,000 996 999 1,000 995 965 3.450% notes due January 2027 750 746 763 750 746 742 3.375% notes due April 2027 625 619 633 625 619 611 2.950% notes due October 2027 950 938 933 950 938 898 3.850% notes due June 2028 1,150 1,142 1,204 1,150 1,142 1,163 3.875% notes due December 2028 850 842 890 850 842 861 4.625% notes due July 2035 1,000 992 1,121 1,000 992 1,060 5.800% notes due March 2036 850 838 1,045 850 838 1,003 6.500% notes due June 2037 500 492 661 500 492 638 6.625% notes due November 2037 650 641 874 650 641 841 6.875% notes due February 2038 1,100 1,076 1,514 1,100 1,076 1,437 5.700% notes due October 2040 300 296 370 300 296 355 5.950% notes due February 2041 350 345 446 350 345 426 4.625% notes due November 2041 600 588 657 600 588 627 4.375% notes due March 2042 502 484 534 502 484 503 3.950% notes due October 2042 625 607 631 625 607 596 4.250% notes due March 2043 750 735 787 750 734 744 4.750% notes due July 2045 2,000 1,973 2,260 2,000 1,973 2,116 4.200% notes due January 2047 750 738 777 750 738 745 4.250% notes due April 2047 725 717 759 725 717 719 3.750% notes due October 2047 950 933 923 950 933 869 4.250% notes due June 2048 1,350 1,329 1,420 1,350 1,329 1,349 4.450% notes due December 2048 1,100 1,087 1,191 1,100 1,087 1,132 Total commercial paper and long-term debt $ 37,551 $ 37,151 $ 39,688 $ 35,667 $ 35,234 $ 36,591 The Company’s long-term debt obligations included $1.2 billion and $1.3 billion of other financing obligations, of which $306 million and $229 million were classified as current as of March 31, 2019 and December 31, 2018 , respectively. Commercial Paper and Bank Credit Facilities Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through broker-dealers. As of March 31, 2019 , the Company’s outstanding commercial paper had a weighted average annual interest rate of 2.7% . The Company has $3.5 billion five-year, $3.5 billion three-year and $3.0 billion 364-day revolving bank credit facilities with 26 banks, which mature in December 2023 , December 2021 and December 2019 , respectively. These facilities provide liquidity support for the Company’s commercial paper program and are available for general corporate purposes. As of March 31, 2019 , no amounts had been drawn on any of the bank credit facilities. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company’s senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities as of March 31, 2019 , annual interest rates would have ranged from 3.2% to 3.4% . Debt Covenants The Company’s bank credit facilities contain various covenants, including covenants requiring the Company to maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60% . The Company was in compliance with its debt covenants as of March 31, 2019 . |
Commitments and Contingencies (
Commitments and Contingencies (Notes) | 3 Months Ended |
Mar. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | Commitments and Contingencies Leases Operating lease costs were $238 million for the three months ended March 31, 2019 and included immaterial variable and short-term lease costs. Cash payments made on the Company’s operating lease liabilities were $181 million for the three months ended March 31, 2019, which were classified within operating activities in the Condensed Consolidated Statements of Cash Flows. As of March 31, 2019, the Company’s weighted-average remaining lease term and weighted-average discount rate for its operating leases were 8.5 years and 4.2% , respectively. As of March 31, 2019, future minimum annual lease payments under all non-cancelable operating leases were as follows: (in millions) Future Operating Lease Payments 2019 480 2020 667 2021 578 2022 481 2023 393 Thereafter 1,553 Total future minimum lease payments 4,152 Less imputed interest (731 ) Total 3,421 Legal Matters Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices. The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred. Government Investigations, Audits and Reviews The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, the Brazilian national regulatory agency for private health insurance and plans (the Agência Nacional de Saúde Suplementar), state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the Brazilian federal revenue service (the Secretaria da Receita Federal), the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Defense Contract Audit Agency and other governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans. On February 14, 2017, the Department of Justice (DOJ) announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges that the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this matter given its procedural status. |
Segment Financial Information (
Segment Financial Information (Notes) | 3 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
Segment Financial Information [Text Block] | Segment Financial Information The Company’s four reportable segments are UnitedHealthcare, OptumHealth, OptumInsight and OptumRx . For more information on the Company’s segments see Part I, Item I, “Business” and Note 13 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2018 10-K. The following tables present reportable segment financial information: Optum (in millions) UnitedHealthcare OptumHealth OptumInsight OptumRx Optum Eliminations Optum Corporate and Eliminations Consolidated Three Months Ended March 31, 2019 Revenues - unaffiliated customers: Premiums $ 46,501 $ 1,012 $ — $ — $ — $ 1,012 $ — $ 47,513 Products — 8 23 8,041 — 8,072 — 8,072 Services 2,141 1,274 754 149 — 2,177 — 4,318 Total revenues - unaffiliated customers 48,642 2,294 777 8,190 — 11,261 — 59,903 Total revenues - affiliated customers — 4,287 1,407 9,613 (359 ) 14,948 (14,948 ) — Investment and other income 254 132 5 14 — 151 — 405 Total revenues $ 48,896 $ 6,713 $ 2,189 $ 17,817 $ (359 ) $ 26,360 $ (14,948 ) $ 60,308 Earnings from operations $ 2,954 $ 626 $ 432 $ 820 $ — $ 1,878 $ — $ 4,832 Interest expense — — — — — — (400 ) (400 ) Earnings before income taxes $ 2,954 $ 626 $ 432 $ 820 $ — $ 1,878 $ (400 ) $ 4,432 Three Months Ended March 31, 2018 Revenues - unaffiliated customers: Premiums $ 43,237 $ 847 $ — $ — $ — $ 847 $ — $ 44,084 Products — 12 23 6,667 — 6,702 — 6,702 Services 2,039 1,188 740 137 — 2,065 — 4,104 Total revenues - unaffiliated customers 45,276 2,047 763 6,804 — 9,614 — 54,890 Total revenues - affiliated customers — 3,606 1,304 9,295 (333 ) 13,872 (13,872 ) — Investment and other income 183 106 2 7 — 115 — 298 Total revenues $ 45,459 $ 5,759 $ 2,069 $ 16,106 $ (333 ) $ 23,601 $ (13,872 ) $ 55,188 Earnings from operations $ 2,400 $ 488 $ 395 $ 770 $ — $ 1,653 $ — $ 4,053 Interest expense — — — — — — (329 ) (329 ) Earnings before income taxes $ 2,400 $ 488 $ 395 $ 770 $ — $ 1,653 $ (329 ) $ 3,724 |
Basis of Presentation Basis of
Basis of Presentation Basis of Presentation (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Basis of presentation [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the SEC ( 2018 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates include medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted. |
Lessee, Leases [Policy Text Block] | The Company leases facilities and equipment under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not implicit in a lease, the Company utilizes its incremental borrowing rate for a period that closely matches the lease term. The Company’s ROU assets are included in other assets, and lease liabilities are included in other current liabilities and other liabilities in the Company’s Condensed Consolidated Balance Sheet. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2016-02, “Leases (Topic 842)” as modified by ASUs 2018-01, 2018-10, 2018-11, 2018-20 and 2019-01 (collectively, ASU 2016-02). Under ASU 2016-02, an entity is required to recognize assets and liabilities for the rights and obligations created by leases on the entity’s balance sheet for both finance and operating leases. The Company adopted ASU 2016-02 using a cumulative-effect upon adoption approach as of January 1, 2019. Upon adoption, the Company recognized $3.3 billion of lease right-of-use (ROU) assets and liabilities for operating leases on its Condensed Consolidated Balance Sheet, of which, $668 million were classified as current liabilities. The adoption of ASU 2016-02 was immaterial to the Company’s consolidated results of operations, equity and cash flows. The Company has included the disclosures required by ASU 2016-02 below and in Note 6, “Commitments and Contingencies” . The Company leases facilities and equipment under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not implicit in a lease, the Company utilizes its incremental borrowing rate for a period that closely matches the lease term. The Company’s ROU assets are included in other assets, and lease liabilities are included in other current liabilities and other liabilities in the Company’s Condensed Consolidated Balance Sheet. The Company has determined that there have been no other recently adopted or issued accounting standards that had, or will have, a material impact on its Condensed Consolidated Financial Statements. |
Investments (Policies)
Investments (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Investment [Line Items] | |
Investment, Policy [Policy Text Block] | At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, noting no significant deterioration since purchase. As of March 31, 2019 , the Company did not have the intent to sell any of the securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. |
Investments (Tables)
Investments (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Short-Term and Long-Term Investments [Table Text Block] | A summary of debt securities by major security type is as follows: (in millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value March 31, 2019 Debt securities - available-for-sale: U.S. government and agency obligations $ 3,610 $ 30 $ (19 ) $ 3,621 State and municipal obligations 6,566 150 (9 ) 6,707 Corporate obligations 15,589 95 (58 ) 15,626 U.S. agency mortgage-backed securities 5,212 37 (51 ) 5,198 Non-U.S. agency mortgage-backed securities 1,471 13 (6 ) 1,478 Total debt securities - available-for-sale 32,448 325 (143 ) 32,630 Debt securities - held-to-maturity: U.S. government and agency obligations 265 — (1 ) 264 State and municipal obligations 31 1 — 32 Corporate obligations 428 1 — 429 Total debt securities - held-to-maturity 724 2 (1 ) 725 Total debt securities $ 33,172 $ 327 $ (144 ) $ 33,355 December 31, 2018 Debt securities - available-for-sale: U.S. government and agency obligations $ 3,434 $ 13 $ (42 ) $ 3,405 State and municipal obligations 7,117 61 (57 ) 7,121 Corporate obligations 15,366 14 (218 ) 15,162 U.S. agency mortgage-backed securities 4,947 11 (106 ) 4,852 Non-U.S. agency mortgage-backed securities 1,376 2 (20 ) 1,358 Total debt securities - available-for-sale 32,240 101 (443 ) 31,898 Debt securities - held-to-maturity: U.S. government and agency obligations 255 1 (2 ) 254 State and municipal obligations 11 — — 11 Corporate obligations 355 — — 355 Total debt securities - held-to-maturity 621 1 (2 ) 620 Total debt securities $ 32,861 $ 102 $ (445 ) $ 32,518 |
Investments by Contractual Maturity [Table Text Block] | The amortized cost and fair value of debt securities as of March 31, 2019 , by contractual maturity, were as follows: Available-for-Sale Held-to-Maturity (in millions) Amortized Cost Fair Value Amortized Fair Due in one year or less $ 3,457 $ 3,455 $ 132 $ 132 Due after one year through five years 12,283 12,304 318 318 Due after five years through ten years 7,314 7,430 131 131 Due after ten years 2,711 2,765 143 144 U.S. agency mortgage-backed securities 5,212 5,198 — — Non-U.S. agency mortgage-backed securities 1,471 1,478 — — Total debt securities $ 32,448 $ 32,630 $ 724 $ 725 |
Fair Value of Available-for-Sale Investments with Gross Unrealized Losses by Investment Type and Length of Time that Individual Securities have been in a Continuous Unrealized Loss Position [Table Text Block] | The fair value of available-for-sale debt securities with gross unrealized losses by security type and length of time that individual securities have been in a continuous unrealized loss position were as follows: Less Than 12 Months 12 Months or Greater Total (in millions) Fair Value Gross Unrealized Losses Fair Value Gross Fair Value Gross March 31, 2019 Debt securities - available-for-sale: U.S. government and agency obligations $ — $ — $ 1,329 $ (19 ) $ 1,329 $ (19 ) State and municipal obligations — — 1,274 (9 ) 1,274 (9 ) Corporate obligations 1,461 (7 ) 5,479 (51 ) 6,940 (58 ) U.S. agency mortgage-backed securities — — 2,979 (51 ) 2,979 (51 ) Non-U.S. agency mortgage-backed securities — — 546 (6 ) 546 (6 ) Total debt securities - available-for-sale $ 1,461 $ (7 ) $ 11,607 $ (136 ) $ 13,068 $ (143 ) December 31, 2018 Debt securities - available-for-sale: U.S. government and agency obligations $ 998 $ (7 ) $ 1,425 $ (35 ) $ 2,423 $ (42 ) State and municipal obligations 1,334 (11 ) 2,491 (46 ) 3,825 (57 ) Corporate obligations 8,105 (109 ) 4,239 (109 ) 12,344 (218 ) U.S. agency mortgage-backed securities 1,296 (22 ) 2,388 (84 ) 3,684 (106 ) Non-U.S. agency mortgage-backed securities 622 (7 ) 459 (13 ) 1,081 (20 ) Total debt securities - available-for-sale $ 12,355 $ (156 ) $ 11,002 $ (287 ) $ 23,357 $ (443 ) |
Fair Value (Tables)
Fair Value (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Financial Assets and Liabilities, Measured at Fair Value Recurring Basis [Table Text Block] | The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices in Active Markets (Level 1) Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Total Fair and Carrying Value March 31, 2019 Cash and cash equivalents $ 12,283 $ 124 $ — $ 12,407 Debt securities - available-for-sale: U.S. government and agency obligations 3,319 302 — 3,621 State and municipal obligations — 6,707 — 6,707 Corporate obligations 17 15,424 185 15,626 U.S. agency mortgage-backed securities — 5,198 — 5,198 Non-U.S. agency mortgage-backed securities — 1,478 — 1,478 Total debt securities - available-for-sale 3,336 29,109 185 32,630 Equity securities 1,827 12 — 1,839 Assets under management 896 2,043 12 2,951 Total assets at fair value $ 18,342 $ 31,288 $ 197 $ 49,827 Percentage of total assets at fair value 37 % 63 % — % 100 % December 31, 2018 Cash and cash equivalents $ 10,757 $ 109 $ — $ 10,866 Debt securities - available-for-sale: U.S. government and agency obligations 3,060 345 — 3,405 State and municipal obligations — 7,121 — 7,121 Corporate obligations 39 14,950 173 15,162 U.S. agency mortgage-backed securities — 4,852 — 4,852 Non-U.S. agency mortgage-backed securities — 1,358 — 1,358 Total debt securities - available-for-sale 3,099 28,626 173 31,898 Equity securities 1,832 13 — 1,845 Assets under management 1,086 1,938 8 3,032 Total assets at fair value $ 16,774 $ 30,686 $ 181 $ 47,641 Percentage of total assets at fair value 35 % 65 % — % 100 % |
Fair Value Measurements, Nonrecurring [Table Text Block] | The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices in Active Markets (Level 1) Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Total Fair Value Total Carrying Value March 31, 2019 Debt securities - held-to-maturity $ 273 $ 172 $ 280 $ 725 $ 724 Long-term debt and other financing obligations — 37,790 — 37,790 35,221 December 31, 2018 Debt securities - held-to-maturity $ 260 $ 65 $ 295 $ 620 $ 621 Long-term debt and other financing obligations $ — $ 37,944 $ — $ 37,944 $ 36,554 |
Medical Costs Payable (Tables)
Medical Costs Payable (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Insurance [Abstract] | |
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] | The following table shows the components of the change in medical costs payable for the three months ended March 31: (in millions) 2019 2018 Medical costs payable, beginning of period $ 19,891 $ 17,871 Acquisitions 35 211 Reported medical costs: Current year 39,239 36,153 Prior years (300 ) (290 ) Total reported medical costs 38,939 35,863 Medical payments: Payments for current year (22,973 ) (21,237 ) Payments for prior years (14,753 ) (13,119 ) Total medical payments (37,726 ) (34,356 ) Medical costs payable, end of period $ 21,139 $ 19,589 |
Commercial Paper and Long-Ter_2
Commercial Paper and Long-Term Debt (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Debt Instrument [Line Items] | |
Commercial Paper and Long-Term Debt [Table Text Block] | Commercial paper and senior unsecured long-term debt consisted of the following: March 31, 2019 December 31, 2018 (in millions, except percentages) Par Value Carrying Value Fair Value Par Value Carrying Value Fair Value Commercial paper $ 3,134 $ 3,117 $ 3,117 $ — $ — $ — 1.700% notes due February 2019 — — — 750 750 749 1.625% notes due March 2019 — — — 500 500 499 2.300% notes due December 2019 500 496 499 500 494 497 2.700% notes due July 2020 1,500 1,498 1,503 1,500 1,498 1,494 Floating rate notes due October 2020 300 299 300 300 299 298 3.875% notes due October 2020 450 445 457 450 443 456 1.950% notes due October 2020 900 897 890 900 897 884 4.700% notes due February 2021 400 400 413 400 398 412 2.125% notes due March 2021 750 748 744 750 747 734 Floating rate notes due June 2021 350 349 350 350 349 347 3.150% notes due June 2021 400 399 404 400 399 400 3.375% notes due November 2021 500 493 508 500 489 503 2.875% notes due December 2021 750 742 754 750 735 748 2.875% notes due March 2022 1,100 1,063 1,107 1,100 1,051 1,091 3.350% notes due July 2022 1,000 997 1,022 1,000 997 1,005 2.375% notes due October 2022 900 895 891 900 894 872 0.000% notes due November 2022 15 12 13 15 12 13 2.750% notes due February 2023 625 610 625 625 602 611 2.875% notes due March 2023 750 758 754 750 750 739 3.500% notes due June 2023 750 747 773 750 746 756 3.500% notes due February 2024 750 745 772 750 745 755 3.750% notes due July 2025 2,000 1,989 2,088 2,000 1,989 2,025 3.700% notes due December 2025 300 298 312 300 298 303 3.100% notes due March 2026 1,000 996 999 1,000 995 965 3.450% notes due January 2027 750 746 763 750 746 742 3.375% notes due April 2027 625 619 633 625 619 611 2.950% notes due October 2027 950 938 933 950 938 898 3.850% notes due June 2028 1,150 1,142 1,204 1,150 1,142 1,163 3.875% notes due December 2028 850 842 890 850 842 861 4.625% notes due July 2035 1,000 992 1,121 1,000 992 1,060 5.800% notes due March 2036 850 838 1,045 850 838 1,003 6.500% notes due June 2037 500 492 661 500 492 638 6.625% notes due November 2037 650 641 874 650 641 841 6.875% notes due February 2038 1,100 1,076 1,514 1,100 1,076 1,437 5.700% notes due October 2040 300 296 370 300 296 355 5.950% notes due February 2041 350 345 446 350 345 426 4.625% notes due November 2041 600 588 657 600 588 627 4.375% notes due March 2042 502 484 534 502 484 503 3.950% notes due October 2042 625 607 631 625 607 596 4.250% notes due March 2043 750 735 787 750 734 744 4.750% notes due July 2045 2,000 1,973 2,260 2,000 1,973 2,116 4.200% notes due January 2047 750 738 777 750 738 745 4.250% notes due April 2047 725 717 759 725 717 719 3.750% notes due October 2047 950 933 923 950 933 869 4.250% notes due June 2048 1,350 1,329 1,420 1,350 1,329 1,349 4.450% notes due December 2048 1,100 1,087 1,191 1,100 1,087 1,132 Total commercial paper and long-term debt $ 37,551 $ 37,151 $ 39,688 $ 35,667 $ 35,234 $ 36,591 |
Commitments and Contingencies_2
Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | As of March 31, 2019, future minimum annual lease payments under all non-cancelable operating leases were as follows: (in millions) Future Operating Lease Payments 2019 480 2020 667 2021 578 2022 481 2023 393 Thereafter 1,553 Total future minimum lease payments 4,152 Less imputed interest (731 ) Total 3,421 |
Segment Financial Information_2
Segment Financial Information (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
Segment Financial Information [Table Text Block] | The following tables present reportable segment financial information: Optum (in millions) UnitedHealthcare OptumHealth OptumInsight OptumRx Optum Eliminations Optum Corporate and Eliminations Consolidated Three Months Ended March 31, 2019 Revenues - unaffiliated customers: Premiums $ 46,501 $ 1,012 $ — $ — $ — $ 1,012 $ — $ 47,513 Products — 8 23 8,041 — 8,072 — 8,072 Services 2,141 1,274 754 149 — 2,177 — 4,318 Total revenues - unaffiliated customers 48,642 2,294 777 8,190 — 11,261 — 59,903 Total revenues - affiliated customers — 4,287 1,407 9,613 (359 ) 14,948 (14,948 ) — Investment and other income 254 132 5 14 — 151 — 405 Total revenues $ 48,896 $ 6,713 $ 2,189 $ 17,817 $ (359 ) $ 26,360 $ (14,948 ) $ 60,308 Earnings from operations $ 2,954 $ 626 $ 432 $ 820 $ — $ 1,878 $ — $ 4,832 Interest expense — — — — — — (400 ) (400 ) Earnings before income taxes $ 2,954 $ 626 $ 432 $ 820 $ — $ 1,878 $ (400 ) $ 4,432 Three Months Ended March 31, 2018 Revenues - unaffiliated customers: Premiums $ 43,237 $ 847 $ — $ — $ — $ 847 $ — $ 44,084 Products — 12 23 6,667 — 6,702 — 6,702 Services 2,039 1,188 740 137 — 2,065 — 4,104 Total revenues - unaffiliated customers 45,276 2,047 763 6,804 — 9,614 — 54,890 Total revenues - affiliated customers — 3,606 1,304 9,295 (333 ) 13,872 (13,872 ) — Investment and other income 183 106 2 7 — 115 — 298 Total revenues $ 45,459 $ 5,759 $ 2,069 $ 16,106 $ (333 ) $ 23,601 $ (13,872 ) $ 55,188 Earnings from operations $ 2,400 $ 488 $ 395 $ 770 $ — $ 1,653 $ — $ 4,053 Interest expense — — — — — — (329 ) (329 ) Earnings before income taxes $ 2,400 $ 488 $ 395 $ 770 $ — $ 1,653 $ (329 ) $ 3,724 |
Basis of Presentation Basis o_2
Basis of Presentation Basis of Presentation, Uses of Estimates and Significant Accounting Policies (Details) - Accounting Standards Update 2016-02 [Member] - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Jan. 01, 2019 | |
New Accounting Pronouncement or Change in Accounting Principle, Description of Transition Method | Cumulative effect upon adoption approach | |
New Accounting Pronouncement, Transition Guidance Not Significant or Not Practical | Impact is not material | |
Operating Lease, Right-of-Use Asset | $ 3,300 | |
Operating Lease, Liability, Current | $ 668 |
Investments (Narrative) (Detail
Investments (Narrative) (Details) $ in Millions | Mar. 31, 2019USD ($) | Dec. 31, 2018USD ($) |
Investment [Line Items] | ||
Equity Securities, FV-NI and without Readily Determinable Fair Value | $ 2,000 | $ 2,000 |
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions | 11,000 | |
Total number of security positions | 30,000 | |
Equity Method Investments | $ 1,500 | $ 1,500 |
Investments (Short-Term and Lon
Investments (Short-Term and Long-Term Investments) (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | $ 32,448 | $ 32,240 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 325 | 101 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (143) | (443) |
Debt Securities, Available-for-sale | 32,630 | 31,898 |
Held-to-maturity securities, Amortized Cost | 724 | 621 |
Securities, Held to maturity, Unrecognized Holding Gain | 2 | 1 |
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | (1) | (2) |
Debt Securities, Held-to-maturity, Fair Value | 725 | 620 |
Total debt securities, Amortized Cost | 33,172 | 32,861 |
Total debt securities, Gross Unrealized Gains | 327 | 102 |
Total debt securities, Gross Unrealized Losses | (144) | (445) |
Debt securities, Fair Value Disclosure | 33,355 | 32,518 |
Debt Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale | 32,630 | 31,898 |
U.S. Government and Agency Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 3,610 | 3,434 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 30 | 13 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (19) | (42) |
Debt Securities, Available-for-sale | 3,621 | 3,405 |
Held-to-maturity securities, Amortized Cost | 265 | 255 |
Securities, Held to maturity, Unrecognized Holding Gain | 0 | 1 |
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | (1) | (2) |
Debt Securities, Held-to-maturity, Fair Value | 264 | 254 |
State and Municipal Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 6,566 | 7,117 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 150 | 61 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (9) | (57) |
Debt Securities, Available-for-sale | 6,707 | 7,121 |
Held-to-maturity securities, Amortized Cost | 31 | 11 |
Securities, Held to maturity, Unrecognized Holding Gain | 1 | 0 |
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | 0 | 0 |
Debt Securities, Held-to-maturity, Fair Value | 32 | 11 |
Corporate Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 15,589 | 15,366 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 95 | 14 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (58) | (218) |
Debt Securities, Available-for-sale | 15,626 | 15,162 |
Held-to-maturity securities, Amortized Cost | 428 | 355 |
Securities, Held to maturity, Unrecognized Holding Gain | 1 | 0 |
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | 0 | 0 |
Debt Securities, Held-to-maturity, Fair Value | 429 | 355 |
U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 5,212 | 4,947 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 37 | 11 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (51) | (106) |
Debt Securities, Available-for-sale | 5,198 | 4,852 |
Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 1,471 | 1,376 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 13 | 2 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (6) | (20) |
Debt Securities, Available-for-sale | $ 1,478 | $ 1,358 |
Investments (Amortized Cost and
Investments (Amortized Cost and Fair Value of Available-for-Sale Debt Securities by Contractual Maturity) (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Schedule of Investments [Line Items] | ||
Due in one year or less, Amortized Cost | $ 3,457 | |
Due after one year through five years, Amortized Cost | 12,283 | |
Due after five years through ten years, Amortized Cost | 7,314 | |
Due after ten years, Amortized Cost | 2,711 | |
Total debt securities - available-for-sale, Amortized Cost | 32,448 | $ 32,240 |
Due in one year or less, Fair Value | 3,455 | |
Due after one year through five years, Fair Value | 12,304 | |
Due after five years through ten years, Fair Value | 7,430 | |
Due after ten years, Fair Value | 2,765 | |
Debt Securities, Available-for-sale | 32,630 | 31,898 |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost | 132 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost | 318 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost | 131 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after 10 Years, Amortized Cost | 143 | |
Held-to-maturity securities, Amortized Cost | 724 | 621 |
Held-to-maturity Securities, Debt Maturities, within One Year, Fair Value | 132 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value | 318 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value | 131 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value | 144 | |
Debt Securities, Held-to-maturity, Fair Value | 725 | 620 |
U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Mortgage-backed securities, Amortized Cost | 5,212 | |
Total debt securities - available-for-sale, Amortized Cost | 5,212 | 4,947 |
Mortgage-backed securities, Fair Value | 5,198 | |
Debt Securities, Available-for-sale | 5,198 | 4,852 |
Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Mortgage-backed securities, Amortized Cost | 1,471 | |
Total debt securities - available-for-sale, Amortized Cost | 1,471 | 1,376 |
Mortgage-backed securities, Fair Value | 1,478 | |
Debt Securities, Available-for-sale | $ 1,478 | $ 1,358 |
Investments (Fair Value of Avai
Investments (Fair Value of Available-For-Sale Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Debt Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | $ 1,461 | $ 12,355 |
Less Than 12 Months, Gross Unrealized Losses | (7) | (156) |
Greater Than 12 Months, Fair Value | 11,607 | 11,002 |
Greater Than 12 Months, Gross Unrealized Losses | (136) | (287) |
Total, Fair Value | 13,068 | 23,357 |
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | (143) | (443) |
U.S. Government and Agency Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 0 | 998 |
Less Than 12 Months, Gross Unrealized Losses | 0 | (7) |
Greater Than 12 Months, Fair Value | 1,329 | 1,425 |
Greater Than 12 Months, Gross Unrealized Losses | (19) | (35) |
Total, Fair Value | 1,329 | 2,423 |
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | (19) | (42) |
State and Municipal Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 0 | 1,334 |
Less Than 12 Months, Gross Unrealized Losses | 0 | (11) |
Greater Than 12 Months, Fair Value | 1,274 | 2,491 |
Greater Than 12 Months, Gross Unrealized Losses | (9) | (46) |
Total, Fair Value | 1,274 | 3,825 |
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | (9) | (57) |
Corporate Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 1,461 | 8,105 |
Less Than 12 Months, Gross Unrealized Losses | (7) | (109) |
Greater Than 12 Months, Fair Value | 5,479 | 4,239 |
Greater Than 12 Months, Gross Unrealized Losses | (51) | (109) |
Total, Fair Value | 6,940 | 12,344 |
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | (58) | (218) |
U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 0 | 1,296 |
Less Than 12 Months, Gross Unrealized Losses | 0 | (22) |
Greater Than 12 Months, Fair Value | 2,979 | 2,388 |
Greater Than 12 Months, Gross Unrealized Losses | (51) | (84) |
Total, Fair Value | 2,979 | 3,684 |
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | (51) | (106) |
Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 0 | 622 |
Less Than 12 Months, Gross Unrealized Losses | 0 | (7) |
Greater Than 12 Months, Fair Value | 546 | 459 |
Greater Than 12 Months, Gross Unrealized Losses | (6) | (13) |
Total, Fair Value | 546 | 1,081 |
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | $ (6) | $ (20) |
Fair Value (Narrative) (Details
Fair Value (Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Fair Value [Line Items] | ||
Transfers Into Level 3 | $ 0 | $ 0 |
Transfers out of Level 3 | 0 | 0 |
Fair Value, Measurements, Nonrecurring [Member] | ||
Fair Value [Line Items] | ||
Significant fair value adjustments for assets and liabilities measured on a nonrecurring basis | $ 0 | $ 0 |
Fair Value (Financial Assets an
Fair Value (Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | $ 12,407 | $ 10,866 |
Debt Securities, Available-for-sale | 32,630 | 31,898 |
Equity Securities, Fair Value | 1,839 | 1,845 |
Assets under management | 2,951 | 3,032 |
Assets, Fair Value Disclosure | 49,827 | 47,641 |
Debt Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 32,630 | 31,898 |
U.S. Government and Agency Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 3,621 | 3,405 |
State and Municipal Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 6,707 | 7,121 |
Corporate Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 15,626 | 15,162 |
U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 5,198 | 4,852 |
Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 1,478 | 1,358 |
Quoted Prices in Active Markets (Level 1) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 12,283 | 10,757 |
Equity Securities, Fair Value | 1,827 | 1,832 |
Assets under management | 896 | 1,086 |
Assets, Fair Value Disclosure | 18,342 | 16,774 |
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 3,336 | 3,099 |
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Government and Agency Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 3,319 | 3,060 |
Quoted Prices in Active Markets (Level 1) [Member] | State and Municipal Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Quoted Prices in Active Markets (Level 1) [Member] | Corporate Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 17 | 39 |
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Quoted Prices in Active Markets (Level 1) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Other Observable Inputs (Level 2) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 124 | 109 |
Equity Securities, Fair Value | 12 | 13 |
Assets under management | 2,043 | 1,938 |
Assets, Fair Value Disclosure | 31,288 | 30,686 |
Other Observable Inputs (Level 2) [Member] | Debt Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 29,109 | 28,626 |
Other Observable Inputs (Level 2) [Member] | U.S. Government and Agency Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 302 | 345 |
Other Observable Inputs (Level 2) [Member] | State and Municipal Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 6,707 | 7,121 |
Other Observable Inputs (Level 2) [Member] | Corporate Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 15,424 | 14,950 |
Other Observable Inputs (Level 2) [Member] | U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 5,198 | 4,852 |
Other Observable Inputs (Level 2) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 1,478 | 1,358 |
Unobservable Inputs (Level 3) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Equity Securities, Fair Value | 0 | 0 |
Assets under management | 12 | 8 |
Assets, Fair Value Disclosure | 197 | 181 |
Unobservable Inputs (Level 3) [Member] | Debt Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 185 | 173 |
Unobservable Inputs (Level 3) [Member] | U.S. Government and Agency Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Unobservable Inputs (Level 3) [Member] | State and Municipal Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Unobservable Inputs (Level 3) [Member] | Corporate Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 185 | 173 |
Unobservable Inputs (Level 3) [Member] | U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Unobservable Inputs (Level 3) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | $ 0 | $ 0 |
Fair Value (Financial Assets _2
Fair Value (Financial Assets and Liabilities, Not Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | $ 725 | $ 620 |
Debt Securities, Held-to-maturity | 724 | 621 |
Debt and other financing obligations, carrying value | 37,151 | 35,234 |
Fair Value, Measurements, Nonrecurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | 725 | 620 |
Debt and other financing obligations | 37,790 | 37,944 |
Fair Value, Measurements, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | 273 | 260 |
Debt and other financing obligations | 0 | 0 |
Fair Value, Measurements, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | 172 | 65 |
Debt and other financing obligations | 37,790 | 37,944 |
Fair Value, Measurements, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | 280 | 295 |
Debt and other financing obligations | 0 | 0 |
Long-term debt and other financing obligations | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt and other financing obligations, carrying value | $ 35,221 | $ 36,554 |
Medical Costs Payable (Narrativ
Medical Costs Payable (Narrative) (Details) - USD ($) $ in Billions | Mar. 31, 2019 | Dec. 31, 2018 |
Liability for Claims and Claims Adjustment Expense [Line Items] | ||
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount | $ 14.3 | $ 13.2 |
Medical Costs Payable Rollforwa
Medical Costs Payable Rollforward (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items] | ||
Medical costs payable, beginning of period | $ 19,891 | $ 17,871 |
Acquisitions | 35 | 211 |
Reported medical costs: | ||
Current year | 39,239 | 36,153 |
Prior years | (300) | (290) |
Total reported medical costs | 38,939 | 35,863 |
Medical payments: | ||
Payments for current year | (22,973) | (21,237) |
Payments for prior years | (14,753) | (13,119) |
Total medical payments | (37,726) | (34,356) |
Medical costs payable, end of period | $ 21,139 | $ 19,589 |
Commercial Paper and Long-Ter_3
Commercial Paper and Long-Term Debt (Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Dec. 31, 2018 | |
Minimum [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate During Period | 3.20% | |
Maximum [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate During Period | 3.40% | |
Five Year $3.5 Billion Credit Facility [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Line of Credit | $ 0 | |
Line of Credit, Credit Facility, Maximum Borrowing Capacity | $ 3,500 | |
Line of Credit Facility, Expiration Period | 5 years | |
Three Year $3.5 Billion Credit Facility [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Line of Credit | $ 0 | |
Line of Credit, Credit Facility, Maximum Borrowing Capacity | $ 3,500 | |
Line of Credit Facility, Expiration Period | 3 years | |
364 Day $3.0 Billion Credit Facility [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Line of Credit, Current | $ 0 | |
Line of Credit, Credit Facility, Maximum Borrowing Capacity | $ 3,000 | |
Line of Credit Facility, Expiration Period | 364 days | |
Subsidiaries [Member] | ||
Debt Instrument [Line Items] | ||
Other Long-term Debt | $ 1,200 | $ 1,300 |
Other Long-term Debt, Current | $ 306 | $ 229 |
Commercial Paper [Member] | ||
Debt Instrument [Line Items] | ||
Short-term Debt, Weighted Average Interest Rate, at Point in Time | 2.70% |
Commercial Paper and Long-Ter_4
Commercial Paper and Long-Term Debt (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Debt Instrument [Line Items] | ||
Par Value | $ 37,551 | $ 35,667 |
Carrying value, Combined Amount | 37,151 | 35,234 |
Fair Value | 39,688 | 36,591 |
Commercial Paper [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | 3,134 | 0 |
Commercial Paper | 3,117 | 0 |
Fair Value | $ 3,117 | 0 |
1.700% Notes due February 2019 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 1.70% | |
Par Value | $ 0 | 750 |
Carrying Value, Current | 0 | 750 |
Fair Value | $ 0 | 749 |
1.625% notes due March 2019 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 1.625% | |
Par Value | $ 0 | 500 |
Carrying Value, Current | 0 | 500 |
Fair Value | $ 0 | 499 |
2.300% notes due December 2019 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.30% | |
Par Value | $ 500 | 500 |
Carrying Value, Current | 496 | 494 |
Fair Value | $ 499 | 497 |
2.700% Notes due July 2020 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.70% | |
Par Value | $ 1,500 | 1,500 |
Carrying Value, Noncurrent | 1,498 | 1,498 |
Fair Value | 1,503 | 1,494 |
Floating rate notes due October 2020 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | 300 | 300 |
Carrying Value, Noncurrent | 299 | 299 |
Fair Value | $ 300 | 298 |
3.875% notes due October 2020 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.875% | |
Par Value | $ 450 | 450 |
Carrying Value, Noncurrent | 445 | 443 |
Fair Value | $ 457 | 456 |
1.950% notes due October 2020 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 1.95% | |
Par Value | $ 900 | 900 |
Carrying Value, Noncurrent | 897 | 897 |
Fair Value | $ 890 | 884 |
4.700% notes due February 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.70% | |
Par Value | $ 400 | 400 |
Carrying Value, Noncurrent | 400 | 398 |
Fair Value | $ 413 | 412 |
2.125% notes due March 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.125% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 748 | 747 |
Fair Value | 744 | 734 |
Floating rate notes due June 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | 350 | 350 |
Carrying Value, Noncurrent | 349 | 349 |
Fair Value | $ 350 | 347 |
3.150% notes due June 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.15% | |
Par Value | $ 400 | 400 |
Carrying Value, Noncurrent | 399 | 399 |
Fair Value | $ 404 | 400 |
3.375% notes due November 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.375% | |
Par Value | $ 500 | 500 |
Carrying Value, Noncurrent | 493 | 489 |
Fair Value | $ 508 | 503 |
2.875% notes due December 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.875% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 742 | 735 |
Fair Value | $ 754 | 748 |
2.875% notes due March 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.875% | |
Par Value | $ 1,100 | 1,100 |
Carrying Value, Noncurrent | 1,063 | 1,051 |
Fair Value | $ 1,107 | 1,091 |
3.350% notes due July 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.35% | |
Par Value | $ 1,000 | 1,000 |
Carrying Value, Noncurrent | 997 | 997 |
Fair Value | $ 1,022 | 1,005 |
2.375% notes due October 2022 [Member] [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.375% | |
Par Value | $ 900 | 900 |
Carrying Value, Noncurrent | 895 | 894 |
Fair Value | $ 891 | 872 |
Zero Coupon notes due November 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | |
Par Value | $ 15 | 15 |
Carrying Value, Noncurrent | 12 | 12 |
Fair Value | $ 13 | 13 |
2.750% notes due February 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.75% | |
Par Value | $ 625 | 625 |
Carrying Value, Noncurrent | 610 | 602 |
Fair Value | $ 625 | 611 |
2.875% notes due March 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.875% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 758 | 750 |
Fair Value | $ 754 | 739 |
3.500% notes due June 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.50% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 747 | 746 |
Fair Value | $ 773 | 756 |
3.500% notes due February 2024 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.50% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 745 | 745 |
Fair Value | $ 772 | 755 |
3.750% notes due July 2025 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.75% | |
Par Value | $ 2,000 | 2,000 |
Carrying Value, Noncurrent | 1,989 | 1,989 |
Fair Value | $ 2,088 | 2,025 |
3.700% notes due December 2025 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.70% | |
Par Value | $ 300 | 300 |
Carrying Value, Noncurrent | 298 | 298 |
Fair Value | $ 312 | 303 |
3.100% notes due March 2026 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.10% | |
Par Value | $ 1,000 | 1,000 |
Carrying Value, Noncurrent | 996 | 995 |
Fair Value | $ 999 | 965 |
3.450% notes due January 2027 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.45% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 746 | 746 |
Fair Value | $ 763 | 742 |
3.375% notes due April 2027 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.375% | |
Par Value | $ 625 | 625 |
Carrying Value, Noncurrent | 619 | 619 |
Fair Value | $ 633 | 611 |
2.950% notes due October 2027 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 2.95% | |
Par Value | $ 950 | 950 |
Carrying Value, Noncurrent | 938 | 938 |
Fair Value | $ 933 | 898 |
3.850% notes due June 2028 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.85% | |
Par Value | $ 1,150 | 1,150 |
Carrying Value, Noncurrent | 1,142 | 1,142 |
Fair Value | $ 1,204 | 1,163 |
3.875% notes due December 2028 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.875% | |
Par Value | $ 850 | 850 |
Carrying Value, Noncurrent | 842 | 842 |
Fair Value | $ 890 | 861 |
4.625% notes due July 2035 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.625% | |
Par Value | $ 1,000 | 1,000 |
Carrying Value, Noncurrent | 992 | 992 |
Fair Value | $ 1,121 | 1,060 |
5.800% notes due March 2036 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 5.80% | |
Par Value | $ 850 | 850 |
Carrying Value, Noncurrent | 838 | 838 |
Fair Value | $ 1,045 | 1,003 |
6.500% Notes Due June 2037 [Member] [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 6.50% | |
Par Value | $ 500 | 500 |
Carrying Value, Noncurrent | 492 | 492 |
Fair Value | $ 661 | 638 |
6.625% Notes due November 2037 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 6.625% | |
Par Value | $ 650 | 650 |
Carrying Value, Noncurrent | 641 | 641 |
Fair Value | $ 874 | 841 |
6.875% notes due February 2038 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 6.875% | |
Par Value | $ 1,100 | 1,100 |
Carrying Value, Noncurrent | 1,076 | 1,076 |
Fair Value | $ 1,514 | 1,437 |
5.700% notes due October 2040 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 5.70% | |
Par Value | $ 300 | 300 |
Carrying Value, Noncurrent | 296 | 296 |
Fair Value | $ 370 | 355 |
5.950% notes due February 2041 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 5.95% | |
Par Value | $ 350 | 350 |
Carrying Value, Noncurrent | 345 | 345 |
Fair Value | $ 446 | 426 |
4.625% notes due November 2041 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.625% | |
Par Value | $ 600 | 600 |
Carrying Value, Noncurrent | 588 | 588 |
Fair Value | $ 657 | 627 |
4.375% notes due March 2042 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.375% | |
Par Value | $ 502 | 502 |
Carrying Value, Noncurrent | 484 | 484 |
Fair Value | $ 534 | 503 |
3.950% notes due October 2042 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.95% | |
Par Value | $ 625 | 625 |
Carrying Value, Noncurrent | 607 | 607 |
Fair Value | $ 631 | 596 |
4.250% notes due March 2043 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.25% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 735 | 734 |
Fair Value | $ 787 | 744 |
4.750% notes due July 2045 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.75% | |
Par Value | $ 2,000 | 2,000 |
Carrying Value, Noncurrent | 1,973 | 1,973 |
Fair Value | $ 2,260 | 2,116 |
4.200% notes due January 2047 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.20% | |
Par Value | $ 750 | 750 |
Carrying Value, Noncurrent | 738 | 738 |
Fair Value | $ 777 | 745 |
4.250% notes due April 2047 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.25% | |
Par Value | $ 725 | 725 |
Carrying Value, Noncurrent | 717 | 717 |
Fair Value | $ 759 | 719 |
3.750% notes due October 2047 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 3.75% | |
Par Value | $ 950 | 950 |
Carrying Value, Noncurrent | 933 | 933 |
Fair Value | $ 923 | 869 |
4.250% notes due June 2048 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.25% | |
Par Value | $ 1,350 | 1,350 |
Carrying Value, Noncurrent | 1,329 | 1,329 |
Fair Value | $ 1,420 | 1,349 |
4.450% notes due December 2048 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.45% | |
Par Value | $ 1,100 | 1,100 |
Carrying Value, Noncurrent | 1,087 | 1,087 |
Fair Value | $ 1,191 | $ 1,132 |
Commitments and Contingencies N
Commitments and Contingencies Narrative (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Leases, Operating [Abstract] | |
Operating Lease, Cost | $ 238 |
Operating Lease, Payments | $ 181 |
Operating Lease, Weighted Average Remaining Lease Term | 8 years 6 months |
Operating Lease, Weighted Average Discount Rate, Percent | 4.20% |
Commitments and Contingencies F
Commitments and Contingencies Future Lease Payments (Details) $ in Millions | Mar. 31, 2019USD ($) |
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] | |
2019 | $ 480 |
2020 | 667 |
2021 | 578 |
2022 | 481 |
2023 | 393 |
Thereafter | 1,553 |
Total future minimum lease payments | 4,152 |
Less imputed interest | (731) |
Total | $ 3,421 |
Segment Financial Information_3
Segment Financial Information (Narrative) (Details) | 3 Months Ended |
Mar. 31, 2019 | |
Statement [Line Items] | |
Number of Reportable Segments | 4 |
Segment Financial Information_4
Segment Financial Information (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | $ 47,513 | $ 44,084 |
Products, revenues - unaffiliated customers | 8,072 | 6,702 |
Services, revenues - unaffiliated customers | 4,318 | 4,104 |
Investment and other income | 405 | 298 |
Total revenues | 60,308 | 55,188 |
Earnings from operations | 4,832 | 4,053 |
Interest expense | (400) | (329) |
Earnings before income taxes | 4,432 | 3,724 |
Optum | ||
Statement [Line Items] | ||
Investment and other income | 151 | 115 |
Total revenues | 26,360 | 23,601 |
Earnings from operations | 1,878 | 1,653 |
Interest expense | 0 | 0 |
Earnings before income taxes | 1,878 | 1,653 |
Unaffiliated Customers | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 47,513 | 44,084 |
Products, revenues - unaffiliated customers | 8,072 | 6,702 |
Services, revenues - unaffiliated customers | 4,318 | 4,104 |
Total revenues | 59,903 | 54,890 |
Unaffiliated Customers | Optum | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 1,012 | 847 |
Products, revenues - unaffiliated customers | 8,072 | 6,702 |
Services, revenues - unaffiliated customers | 2,177 | 2,065 |
Total revenues | 11,261 | 9,614 |
Affiliated Customers | ||
Statement [Line Items] | ||
Total revenues | 0 | 0 |
Affiliated Customers | Optum | ||
Statement [Line Items] | ||
Total revenues | 14,948 | 13,872 |
Operating Segments | UnitedHealthcare | ||
Statement [Line Items] | ||
Investment and other income | 254 | 183 |
Total revenues | 48,896 | 45,459 |
Earnings from operations | 2,954 | 2,400 |
Interest expense | 0 | 0 |
Earnings before income taxes | 2,954 | 2,400 |
Operating Segments | OptumHealth | ||
Statement [Line Items] | ||
Investment and other income | 132 | 106 |
Total revenues | 6,713 | 5,759 |
Earnings from operations | 626 | 488 |
Interest expense | 0 | 0 |
Earnings before income taxes | 626 | 488 |
Operating Segments | OptumInsight | ||
Statement [Line Items] | ||
Investment and other income | 5 | 2 |
Total revenues | 2,189 | 2,069 |
Earnings from operations | 432 | 395 |
Interest expense | 0 | 0 |
Earnings before income taxes | 432 | 395 |
Operating Segments | OptumRx | ||
Statement [Line Items] | ||
Investment and other income | 14 | 7 |
Total revenues | 17,817 | 16,106 |
Earnings from operations | 820 | 770 |
Interest expense | 0 | 0 |
Earnings before income taxes | 820 | 770 |
Operating Segments | Unaffiliated Customers | UnitedHealthcare | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 46,501 | 43,237 |
Products, revenues - unaffiliated customers | 0 | 0 |
Services, revenues - unaffiliated customers | 2,141 | 2,039 |
Total revenues | 48,642 | 45,276 |
Operating Segments | Unaffiliated Customers | OptumHealth | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 1,012 | 847 |
Products, revenues - unaffiliated customers | 8 | 12 |
Services, revenues - unaffiliated customers | 1,274 | 1,188 |
Total revenues | 2,294 | 2,047 |
Operating Segments | Unaffiliated Customers | OptumInsight | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 0 | 0 |
Products, revenues - unaffiliated customers | 23 | 23 |
Services, revenues - unaffiliated customers | 754 | 740 |
Total revenues | 777 | 763 |
Operating Segments | Unaffiliated Customers | OptumRx | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 0 | 0 |
Products, revenues - unaffiliated customers | 8,041 | 6,667 |
Services, revenues - unaffiliated customers | 149 | 137 |
Total revenues | 8,190 | 6,804 |
Operating Segments | Affiliated Customers | UnitedHealthcare | ||
Statement [Line Items] | ||
Total revenues | 0 | 0 |
Operating Segments | Affiliated Customers | OptumHealth | ||
Statement [Line Items] | ||
Total revenues | 4,287 | 3,606 |
Operating Segments | Affiliated Customers | OptumInsight | ||
Statement [Line Items] | ||
Total revenues | 1,407 | 1,304 |
Operating Segments | Affiliated Customers | OptumRx | ||
Statement [Line Items] | ||
Total revenues | 9,613 | 9,295 |
Optum Eliminations | ||
Statement [Line Items] | ||
Investment and other income | 0 | 0 |
Total revenues | (359) | (333) |
Earnings from operations | 0 | 0 |
Interest expense | 0 | 0 |
Earnings before income taxes | 0 | 0 |
Optum Eliminations | Unaffiliated Customers | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 0 | 0 |
Products, revenues - unaffiliated customers | 0 | 0 |
Services, revenues - unaffiliated customers | 0 | 0 |
Total revenues | 0 | 0 |
Optum Eliminations | Affiliated Customers | ||
Statement [Line Items] | ||
Total revenues | (359) | (333) |
Corporate and Eliminations | ||
Statement [Line Items] | ||
Investment and other income | 0 | 0 |
Total revenues | (14,948) | (13,872) |
Earnings from operations | 0 | 0 |
Interest expense | (400) | (329) |
Earnings before income taxes | (400) | (329) |
Corporate and Eliminations | Unaffiliated Customers | ||
Statement [Line Items] | ||
Premiums, revenues - unaffiliated customers | 0 | 0 |
Products, revenues - unaffiliated customers | 0 | 0 |
Services, revenues - unaffiliated customers | 0 | 0 |
Total revenues | 0 | 0 |
Corporate and Eliminations | Affiliated Customers | ||
Statement [Line Items] | ||
Total revenues | $ (14,948) | $ (13,872) |